A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma

Protocol: 
AAAR4308
Phase: 
II

A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma

Are you Eligible? (Inclusion Criteria)

1. Patients must have confirmed unresectable or metastatic Epithelioid
Hemangioendothelioma (EHE).
2.Patients must have measurable disease defined as ≥ 2 cm with conventional
techniques or ≥ 1cm on spiral CT scan.
3. Patients previously treated with drug therapy for EHE are eligible.
4. Patients must be 18 years or older.
5. Patients must have ECOG performance status of ≤ 2 or Karnofsky ≥ 60%

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States